CGH
MYGN icon

Crossmark Global Holdings’s Myriad Genetics MYGN Stock Holding History

Crossmark Global Holdings’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-7,590
Closed -$209K – 1373
2021
Q4 		$209K Buy
7,590
+600
+9% +$17.4K ﹤0.01% 1321
2021
Q3 		$226K Sell
6,990
-80
-1% -$2.66K 0.01% 1288
2021
Q2 		$216K Buy
7,070
+80
+1% +$2.31K 0.01% 1346
2021
Q1 		$213K Buy
+6,990
New +$198K 0.01% 1347
2019
Q2 		– Sell
-6,858
Closed -$228K – 1397
2019
Q1 		$228K Sell
6,858
-30
-0.4% -$913 0.01% 1253
2018
Q4 		$200K Sell
6,888
-8,160
-54% -$294K 0.01% 1300
2018
Q3 		$692K Sell
15,048
-150
-1% -$6.67K 0.02% 759
2018
Q2 		$568K Buy
15,198
+560
+4% +$18.9K 0.02% 865
2018
Q1 		$433K Sell
14,638
-2,158
-13% -$73K 0.01% 1015
2017
Q4 		$577K Sell
16,796
-1,302
-7% -$43.9K 0.01% 887
2017
Q3 		$655K Buy
+18,098
New +$516K 0.02% 796
2016
Q3 		$655K Buy
+18,098
New +$459K 0.02% 796

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Crossmark Global Holdings's MYGN Position: Q1 2022 in Review

Crossmark Global Holdings sold out of Myriad Genetics (MYGN) in Q1 2022, closing a stake of 7,590 shares — an estimated $209K sold.

Crossmark Global Holdings first reported a position in MYGN in Q3 2016 and held it in 12 quarters. The position peaked at $692K in Q3 2018. 205 funds tracked by Wall St. Rank hold MYGN as of Q1 2022.

  • Crossmark Global Holdings reported no remaining Myriad Genetics position as of Q1 2022 after selling out during the quarter.
  • Crossmark Global Holdings sold 7,590 Myriad Genetics shares in Q1 2022, an estimated $209K.
  • Crossmark Global Holdings first reported a position in Myriad Genetics in Q3 2016 and held it in 12 quarters.
  • Crossmark Global Holdings's Myriad Genetics position peaked at $692K in Q3 2018.
  • 205 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2022.

Based on Crossmark Global Holdings's 13F filing for Q1 2022, filed 11 May 2022.